Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;15(6):2338-2348.
doi: 10.1002/jcsm.13564. Epub 2024 Oct 8.

Association between dynapenic obesity and risk of cardiovascular disease: The Hisayama study

Affiliations

Association between dynapenic obesity and risk of cardiovascular disease: The Hisayama study

Yu Setoyama et al. J Cachexia Sarcopenia Muscle. 2024 Dec.

Abstract

Background: Dynapenic obesity is a condition characterized by high adiposity levels combined with muscle dysfunction. Although high adiposity and muscle loss/dysfunction are thought to synergistically increase the risk of cardiovascular disease (CVD), few studies have addressed the association between dynapenic and sarcopenic obesity and CVD. We aimed to investigate the association of dynapenic obesity with incident CVD events using the data from a population-based prospective longitudinal study in Japan.

Methods: A total of 2490 community-dwelling Japanese aged 40-79 years (42.5% males, mean age 57.7 ± 10.6 years) without a history of CVD were followed up for a median of 24 years. Handgrip strength was classified as low, medium, or high by age- and sex-specific tertiles. Body mass index (BMI) levels were categorized as lean (<18.5 kg/m2), normal (18.5-24.9 kg/m2), or obese (≥25.0 kg/m2). Dynapenic obesity was defined as having both low handgrip strength and obesity. The outcomes were defined as the first-ever development of CVD (defined as stroke or coronary heart disease). The hazard ratios (HRs) and their 95% confidence intervals (CIs) for the development of CVD were estimated using a Cox proportional hazards model, in which participants with high handgrip strength and normal BMI were used as a reference group. Mediation analyses used serum high-sensitivity C-reactive protein (hs-CRP) and homeostatic model assessment for insulin resistance (HOMA-IR) as mediators.

Results: During the follow-up period, 482 participants developed CVD events (324 cases of stroke and 209 of coronary heart disease). The multivariable-adjusted risk of CVD increased significantly among participants with dynapenic obesity compared with the reference group (HR 1.49, 95% CI 1.03-2.17). An analysis by age groups showed a further increase in the risk of CVD among participants with dynapenic obesity aged less than 65 years (HR 1.66, 95% CI 1.04-2.65). In mediation analyses for participants aged less than 65 years, serum hs-CRP was shown to be a significant mediator explaining 13.8% of the association between dynapenic obesity and the development of CVD, while HOMA-IR explained 12.2% of this relationship.

Conclusions: Dynapenic obesity was a significant risk factor for the development of CVD in a general Japanese population. This association was more pronounced among those aged <65 years. Inflammation, and possibly glucose metabolism, might partly mediate this association. Our findings suggest that preventing muscle dysfunction as well as appropriate weight control, especially in middle-age, are important for preventing the development of CVD.

Keywords: Body mass index; Cardiovascular disease; Dynapenic obesity; Handgrip strength.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Age‐ and sex‐adjusted incidence of cardiovascular disease and its subtypes according to BMI and handgrip strength classification, 1988–2012. *P < 0.05, **P < 0.01 versus a reference group (participants with a high handgrip strength and BMI of 18.5–24.9 kg/m2). BMI, body mass index; PYs, person‐years.
Figure 2
Figure 2
The causal mediation analyses for examining the mediating role of inflammation, as measured by serum hs‐CRP levels, and insulin resistance, as measured by HOMA‐IR, on the association between dynapenic obesity and the development of cardiovascular disease. The analyses were conducted for all participants (A, B) and for those aged <65 years (C, D). *P < 0.05 versus a reference group (participants with a high handgrip strength and BMI of 18.5–24.9 kg/m2). HR, hazard ratio; hs‐CRP, high‐sensitivity C‐reactive protein; HOMA‐IR, homeostatic model assessment for insulin resistance.

References

    1. Cruz‐Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31. - PMC - PubMed
    1. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300–307. - PubMed
    1. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001;137:231–243. - PubMed
    1. Clark BC, Manini TM. What is dynapenia? Nutrition 2012;28:495–503. - PMC - PubMed
    1. Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci 2012;67:28–40. - PMC - PubMed